Lidak deal

LDAKA signed a letter of intent to purchase Scherer Healthcare Inc.'s Biofor Inc. rational drug design subsidiary for up to $10 million in LDAKA common stock. Biofor (Waverly, Penn.) uses expert systems technology to identify small molecule drug candidates. Biofor has several anti-inflammatory and anti-fungal compounds in preclinical development, and is synthesizing compounds for potential application in respiratory diseases and atherosclerosis. ...